12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Company News  |  Deals

Life Technologies, Novartis deal

Life Technologies granted Novartis exclusive rights to use Dynabeads CD3/CD28 Cell Therapy Systems (CTS) for immunotherapies involving T cells modified to...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >